Progression of NHL compromised the efficacy of CD47-blocking antibody. (A) Raji-engrafted mice were treated with aCD47 at different days and tumor burden was recorded on day 22 after engraftment; ***P < .001 (1-way ANOVA test); ns, not significant. (B) CD47-blocking antibody administration (7.5 mg/kg) at different days differentially influenced the survival of NHL-bearing mice. Mice in the day 4 treatment group stayed alive and were euthanized upon completion of the experiment on day 50 (dotted line). **P < .01, ***P < .001 (log-rank [Mantel-Cox] test). (C) Evaluation of the phagocytic ability of BM macrophages from control mice and NHL-bearing mice (day 11 upon engraftment) with microscopy-based phagocytosis assay in the presence of CD47 blocking antibody. **P < .01 (1-way ANOVA test).